FDA Clears Ocugen’s Phase II/III Trial for Stargardt Disease Gene Therapy
Ocugen’s OCU410ST gene therapy gets another green light. Next stop: a Phase II/III trial. The U.S. Food and Drug Administration…
CONFERENCE COVERAGE
Ocugen’s OCU410ST gene therapy gets another green light. Next stop: a Phase II/III trial. The U.S. Food and Drug Administration…
CONFERENCE COVERAGE